GT BIOPHARMA, INC.
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212

 
 
September 26, 2019
 
VIA EDGAR
 
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
 
 
Re:
GT Biopharma, Inc.
 
 
Registration Statement on Form S-1 (File No. 333-233748)
 
 
Request for Acceleration of Effective Date
 
Ladies and Gentlemen:
 
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-233748) and declare the Registration Statement effective as of Wednesday, October 2, 2019, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.
 
Please contact the undersigned at (407) 808-7704, or Gary R. Henrie, Attorney at Law at (307) 200-9415, with any questions. Also, please notify Mr. Henrie when this request for acceleration has been granted.
 
 
Very truly yours,
 
GT Biopharma, Inc.
 
 
 
 
 
 
By:
/s/ Steven Weldon
 
 
 
Name: Steven Weldon
Title: Chief Financial Officer
 
 
 
 
 
cc: Gary R. Henrie, Attorney at Law